The effects of bicarbonate and its combination with chelating agents used for the removal of depleted uranium in rats

Hemoglobin

Volumn 32, Issue 1-2, 2008, Pages 191-198

  Fukuda, Satoshi ^a   Ikeda, Mizuyo ^a   Nakamura, Mariko ^a   Katoh, Akira ^b   Yan, Xueming ^c   Xie, Yuyuan ^c   Kontoghiorghes, George J ^d  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b SEIKEI UNIVERSITY   (Japan)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^d Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Bicarbonate; Chelating agent; Deferiprone (L1); Depleted uranium (DU)

Indexed keywords

4,6 DIMETHYL 1 HYDROXYPRYRIMIDIN 2(1H) ONE; BICARBONATE; CATECHOL 3,6 BIS(METHYLENEIMINODIACETIC ACID; CHELATING AGENT; DEFERIPRONE; ETHANE 1 HYDROXY 1,1 BISPHOSPHONIC ACID; UNCLASSIFIED DRUG; URANIUM; URANIUM 235; URANIUM 238; URANIUM DERIVATIVE; URANIUM NITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFECT; DRUG POTENTIATION; INTOXICATION; LONG TERM EXPOSURE; MALE; METAL METABOLISM; MONOTHERAPY; NONHUMAN; RADIATION EXPOSURE; RADIOACTIVITY; RAT; URANIUM INTOXICATION; WISTAR RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BICARBONATES; CHELATING AGENTS; CHELATION THERAPY; CREATININE; MALE; NITROGEN; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RATS; RATS, WISTAR; URANIUM;

RATTUS;

EID: 39349098933     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701727093     Document Type: Conference Paper

References (13)

1. Craft E, Abu-Qare A, Flaherty M, Garofolo M, Rincavage H, Abou-Donia M. Depleted and natural uranium: chemistry and toxicological effects. J Toxicol Environ Health B Crit Rev 2004; 7(4):297-317.
2. Moulin C, Laszak I, Moulin V, Tondre C. Time-resolved laser-induced fluorescence as a unique tool for low-level uranium speciation. Appl Spectrosc 1998; 52(4):528-535.
3. Muller D, Houpert P, Cambar J, Henge-Napoli MH. Role of the sodium-dependent phosphate c-transporters and of the phosphate complexes of uranyl in the cytotoxicity of uranium in LLC-PK1 cells. Toxicol Appl Pharmacol 2006; 214(2):166-177.
4. Vidaud C, Dedieu A, Basset C, Plantevin S, Dany I, Pible O, Quemeneur E. Screening of human serum proteins for uranium binding. Chem Res Toxicol 2005; 18(6):946-953.
5. Henge-Napoli MH, Archimbaud M, Ansoborlo E, Metivier H, Gourmelon P. Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in rat after acute administration. Int J Radiat Biol 1995; 68(4):389-393.
6. Fukuda S, Ikeda M, Anzai K, Suzuki M, Katoh A, Kontoghiorghes GJ. Radiation protection by deferiprone in animal models. Hemoglobin 2006; 30(2):201-208.
7. Fukuda S, Iida H, Ikeda M, Yan X, Xie Y. Toxicity of uranium and the removal effects of CBMIDA and EHBP in simulated wounds of rats. Health Phys 2005; 89(1):81-89.
8. Fukuda S, Ikeda M, Nakamura M, Yan X, Xie Y. Effects of pH on DU intake and DU removal by CBMIDA and EHBP. Health Phys 2007; 92(1):10-14.
9. Henge-Napoli MH, Ansoborlo E, Chazei V, Houpert P, Paquest F, Gourmelon P. Efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats. Int J Radiat Biol 1999; 75(11):1473-1477.
10. Martinez AB, Cabrini RL, Ubios AM. Orally administered ethane-1-hydroxy-1,1-bisphosphonate reduces the lethal effects of oral uranium poisoning. Health Phys 2000; 78(6):668-671.
11. Pashalidis L, Kontoghiorghes GJ. Effective complex formation in the interaction of 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with uranium (VI). J Radioanalytic Nuclear Chem 1999; 242(1):181-184.
12. Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferipronr (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16):2161-2183.
13. Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. Advanced in iron overload therapics. Prospects for effecive use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAII and their combinations. Curr Med Chem 2005; 12(23):2663-2681.